Treatment of PTC cell lines with recombinant FGFR1 leads to FGFR pathway signaling activation, leading to ERK and AKT phosphorylation, EMT, and to the development of a more aggressive phenotype of tumor cells. This evidence concerns the gene AKT1 and neoplasm.